1. Introduction {#sec1}
===============

Breast cancer is one of the most common cancers, with greater than 279,100 cases and 42,690 deaths in 2020 in the United States \[[@bib1]\]. Pathologically, breast cancer is a heterogeneous entity with over 20 histological types \[[@bib2], [@bib3], [@bib4]\]. Of these distinct histological types, invasive ductal carcinoma (IDC) is the most common one, accounting for approximately 80% of all breast cancer cases \[[@bib5], [@bib6], [@bib7]\]. Other histological types included invasive lobular carcinoma, adenoid cystic carcinoma, medullary carcinoma, metaplastic carcinoma and so on \[[@bib5],[@bib6]\]. Histological type has been proved to play an important role in breast cancer prognosis \[[@bib8],[@bib9]\]. For example, patients with the medullary carcinoma have been shown to have better prognosis whereas metaplastic carcinoma is associated with a worse prognosis \[[@bib10],[@bib11]\]. Therefore, the histological classification of breast cancer is of great prognostic value and worth a further research to explore the genomic background of each histological type.

Mucinous adenocarcinoma (MC) of the breast is a rare histological type of breast cancer characterized by large amount of extracellular mucin \[[@bib12]\]. In this type of cancer, the tumor is made up of abnormal cells that "float" in pools of mucin, a key ingredient in the slimy, slippery substance known as mucus \[[@bib13]\]. It accounts for 1--6% of all invasive breast cancers \[[@bib14]\]. MC has been classified into two subgroups, the "pure" type consists exclusively of tumor tissue with extracellular mucin production, while the "mixed" type is defined as a tumor where 50--90% of the area is mucinous and also admixing with infiltrating ductal epithelial component \[[@bib15]\]. These two subgroups have several fundamental differences in clinicopathogical features and outcomes \[[@bib16]\]. Recently, a new subgroup of the "mixed" type of MC, the MC with micropapillary features, was reported to be morphologically, clinically and genetically distinct from pure MC of breast \[[@bib17]\]. In previous studies with relatively small patient numbers, MC has been exhibited to have less lymph nodes invasion, lower stage, more expression of estrogen and progestogen receptors (ER and PR) and less human epidermal receptor 2 (HER2) overexpression compared to IDC \[[@bib12],[@bib18], [@bib19], [@bib20], [@bib21]\]. Genetically, MC has been illustrated to have a specific molecular identity different from invasive ductal carcinoma, such as the lower genomic instability \[[@bib22],[@bib23]\]. There also existed genetic heterogeneity within the subgroups of MC. For example, MC with the micropapillary features was illustrated to have subtype specific *GATA3*, *TP53* and *SF3B1* mutation and 17q and 20q gains as well as 17p losses \[[@bib17],[@bib24]\]. However, because of relative rarity of MC patients, the clinicopathological characteristics, prognostic value and genomic features of MC are not well-established.

By using the clinicopathological data from the Surveillance, Epidemiology and End Results (SEER) database and genomic data from The Cancer Genome Atlas (TCGA) database, our study aimed to investigate the clinicopathological characteristics and genomic features of MC by comparing it with IDC.

2. Materials and methods {#sec2}
========================

2.1. Database {#sec2.1}
-------------

Data for this study were obtained from the recent SEER 18 registry research database (November 2015 Submission). The SEER 18 database contains data from the SEER 13 registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey, rural Georgia, and the Alaska Native Tumor Registry) and the registries of greater California, Kentucky, Louisiana, New Jersey, and greater Georgia. The SEER database of the National Cancer Institute (NCI) is the largest population-based cancer registry in the United States and covers approximately 28% of the population (<http://seer.cancer.gov/about/>). All the data included in the present study were obtained with the approval of the independent ethics committee/institutional review board at Ethical Committee of Yuyao People's Hospital of Zhejiang Province.

2.2. Study population {#sec2.2}
---------------------

Our data were obtained from the SEER database released in April 2019, which includes data from 18 population-based registries (1973--2015). The inclusion criteria were as follows: female patients, diagnosis year from 2010 to 2015, histological grades I-IV (Grade IV is the undifferentiated \[UD\] type), American Joint Committee on Cancer (AJCC) stages I-III, pathologic confirmation of infiltrating ductal carcinoma-not otherwise specified (IDC-NOS, ICD-O-3 8500/3) and infiltrating mucinous carcinoma (ICD-O-3 8480/3), unilateral breast cancer, breast cancer as the first and only cancer diagnosis, diagnosis not obtained from a death certificate or autopsy, only one primary site, and known ER and PR status. In all, 186,497 patients were selected, including 4578 MC patients and 181,919 IDC patients.

An analysis of the demographic and clinical characteristics of the IDC and MC subtypes included age at diagnosis, race, grade, ER, PR and HER2 status, T and N stage, radiation, chemotherapy and surgery type. The age at diagnosis was also considered as a continuous variable. Grade 3 and undifferentiated grade were merged into a single group. In addition, the types of radiation were summarized as yes, no or unknown; the types of surgery were classified as no surgery, lumpectomy, mastectomy or unknown. Detailed classification information is described in [Table 1](#tbl1){ref-type="table"}. All unknown data were excluded from the Cox analysis and subgroup analysis but were included in the generation of the Kaplan-Meier curves.Table 1Baseline clinicopathological characteristics of IDC and MC patients.Table 1VariableIDCMCPn%n%**Age at diagnosis (years)**\<0.001**Mean**5965**Marital status**[a](#tbl1fna){ref-type="table-fn"}0.615**Married**145,70980.1%364079.5%**Not married**27,26915.0%70815.5%**Unknown**89414.9%2305.0%**Race**[b](#tbl1fnb){ref-type="table-fn"}\<0.001**White**141,93578.0%345575.5%**Black**20,30711.2%53911.8%**Asian**17,2659.5%52911.6%**Other**24121.3%551.2%**Grade**[c](#tbl1fnc){ref-type="table-fn"}\<0.001**1**37,68420.7%256456.0%**2**73,43040.4%157234.3%**3**65,45036.0%1553.4%**Unknown**53552.9%2876.3%**T stage**\<0.001**T1**115,12963.3%305066.6%**T2**54,39329.9%126327.6%**T3**82134.5%2134.7%**T4**39762.2%501.1%**Unknown**2080.1%20.0%**N stage**\<0.001**N0**126,13469.3%416190.9%**N1**41,74422.9%3437.5%**N2**91975.1%541.2%**N3**48122.6%200.4%**Unknown**320.0%00.0%**ER status**\<0.001**Negative**34,16818.8%481.0%**Positive**144,99579.7%445697.3%**Unknown**27561.5%741.6%**PR status**\<0.001**Negative**51,80128.5%3698.1%**Positive**126,77969.7%412090.0%**Unknown**33371.8%892.0%**HER2 status**\<0.001**Negative**142,58578.4%410889.7%**Positive**29,54816.2%2335.1%**Unknown**97865.3%2375.2%**Radiation**\<0.001**No**74,54341.0%211646.2%**Yes**100,59755.3%236051.6%**Unknown**67793.8%1022.3%**Chemotherapy**\<0.001**No**102,65756.4%399987.4%**Yes**79,26243.6%57912.6%**Surgery**\<0.001**Lumpectomy**109,84860.4%314168.6%**Mastectomy**71,63239.4%142531.1%**Unknown**4390.2%120.2%[^1][^2][^3][^4][^5]

2.3. Gene set enrichment analysis (GSEA) {#sec2.3}
----------------------------------------

GSEA was performed with the GSEA software (v3.0) and the Molecular Signature Database (v6.1) (<http://www.broad.mit.edu/gsea/>). One thousand total permutations were used, IDC versus MC was used as phenotype labels. The permutation type was set to "phenotype".

2.4. Comparison of somatic mutations and copy number alterations {#sec2.4}
----------------------------------------------------------------

Genes with mutation frequencies greater than 0% in IDC or MC were included in our comparison. P value less than 0.05 was considered significant. As most gene was low-frequency mutated genes, we conducted permutation test ("chisq_test" function in R program) to conduct the comparison. The log2 ratio of the copy numbers of each gene was compared between IDC and MC as well. P value less than 0.0 was considered significant. Chromosome fragments with more than three continuous significant genes were considered as significant peaks.

2.5. Statistical analysis {#sec2.5}
-------------------------

The demographic and clinical characteristics of the included cases were compared across groups by the Pearson Chi-square test or Fisher's exact test for categorical nominal data and by the Cochran-Mantel Haenszel (CMH) Chi-square test for categorical ordinal data. The BCSS and OS were considered as the primary and secondary outcomes of our study, respectively. BCSS was defined afs the time from the date of diagnosis to the date of death caused by breast cancer. The OS was defined as the time from the date of diagnosis to the date of death from any cause. Kaplan-Meier curves and log-rank tests were generated with the function "Surv" and "survfit" (R package: survival and rms). Additionally, univariate and multivariate Cox proportional hazard models with HRs and 95% CIs were applied to estimate the factors associated with the BCSS and OS. Subgroup analysis and forest plots were generated with the function "forestplot" (R package: forestplot). All statistical analyses were performed using R version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS version 17.0 (IBM SPSS Statistics, Chicago, IL, USA). A two-sided P value \< 0.001 was considered statistically significant in the comparison of clinicopathological characteristics. Two-sided P values \< 0.05 were considered statistically significant in other tests.

3. Results {#sec3}
==========

3.1. Demographic and clinical characteristics {#sec3.1}
---------------------------------------------

We summarized the demographic and clinical characteristics of all 186,497 selected patients in [Table 1](#tbl1){ref-type="table"}, including 4578 MC patients and 181,919 IDC patients. MC patients were significantly older than IDC patients (median age at diagnosis \[years\]: 65 vs 59, P \< 0.001). Additionally, MC patients had strikingly lower grade tumors (Grade 1: 56.0% vs 20.7%, P \< 0.001), lower N stage (N0: 90.9% vs 69.3%, P \< 0.001), higher proportion of cases with a positive ER and PR status (97.3% vs 79.7%, P \< 0.001; % 90.0 vs 69.7%, P \< 0.001, respectively) and lower proportion of cases with a positive HER2 status (5.1% vs 16.2%, P \< 0.001) compared with IDC patients. Moreover, in terms of treatment, MC patients had lower proportion of receiving radiation, chemotherapy and mastectomy (51.6% vs 55.3%, P \< 0.001; 12.6% vs 43.6%, P \< 0.001; 31.1% vs 39.4%, P \< 0.001, respectively). These data suggested that MC has distinct baseline characteristics from IDC.

3.2. Survival analysis {#sec3.2}
----------------------

We compared the prognosis of these histological types within the 30.2-month median follow-up period. Kaplan-Meier plots were used to evaluate the BCSS and overall survival (OS) for IDC and MC ([Fig. 1](#fig1){ref-type="fig"}). In comparison with IDC patients, MC patients had a significantly better BCSS (log-rank test P \< 0.001). However, IDC and MC patients had insignificant difference in OS comparison (log-rank test P = 0.4).Fig. 1**Survival analysis of mucinous carcinoma**. Kaplan-Meier curves of breast cancer-specific survival (BCSS) **(A)** and of overall survival (OS) **(B)** according to histological type in all patients. Log-rank tests were compared between MC and IDC. Abbreviations: MC: mucinous carcinoma; IDC: invasive ductal carcinoma; BCSS: breast cancer-specific survival; OS: overall survival.Fig. 1

The Cox proportional hazards model was used to further investigate the effect of the baseline characteristics of the disease on BCSS and OS ([Table 2](#tbl2){ref-type="table"}). It was suggested that patients with MC exhibited a better BCSS than patients with IDC (hazard ratio \[HR\] = 0.22, 95% confidence interval \[CI\]: 0.15--0.32, P \< 0.001), while no significant difference was observed in the OS between patients with MC and those with IDC (HR = 0.96, 95% CI: 0.83--1.10, P = 0.526). These significant variables were then included in the multivariate analysis to confirm their prognostic effect ([Table 2](#tbl2){ref-type="table"}). Most of the variables remained significant prognostic predictors in the multivariate analysis. However, after adjusting for other prognostic predictors, MC was no longer an independent prognostic predictor of BCSS compared with IDC (HR = 0.75, 95% CI: 0.51--1.09, P = 0.125). In contrary, MC independently predicted worse OS compared with IDC (HR = 1.36, 95% CI: 1.16--1.57, P \< 0.001). We concluded that the prognostic value of MC was cofounded by some other clinicopathological variables.Table 2Multivariate analysis of breast cancer-specific survival (BCSS) and overall survival (OS) predictors using a cox proportional hazards model.Table 2VariablesBCSSOSHR (95% CI)PHR (95% CI)PHistological type**MC**0.75 (0.51--1.09)0.1251.35 (1.16--1.57)\<0.001**IDC**Reference**Age at diagnosis≤ 60 y**0.66 (0.62--0.69)\<0.0010.44 (0.42--0.46)\<0.001**\> 60 y**Reference**Race**[a](#tbl2fna){ref-type="table-fn"}**Black**1.26 (1.17--1.35)\<0.0011.22 (1.16--1.30)\<0.001**Asian**0.69 (0.61--0.77)\<0.0010.62 (0.56--0.68)\<0.001**White**Reference**Grade**[b](#tbl2fnb){ref-type="table-fn"}**1**0.21 (0.18--0.25)\<0.0010.50 (0.46--0.54)\<0.001**2**0.50 (0.46--0.54)\<0.0010.64 (0.60--0.67)\<0.001**3**Reference**T stageT1**0.18 (0.16--0.20)\<0.0010.20 (0.18--0.22)\<0.001**T2**0.41 (0.37--0.45)\<0.0010.41 (0.37--0.44)\<0.001**T3**0.73 (0.66--0.81)\<0.0010.70 (0.63--0.77)\<0.001**T4**Reference**N stageN0**0.15 (0.14--0.17)\<0.0010.22 (0.21--0.24)\<0.001**N1**0.35 (0.32--0.38)\<0.0010.38 (0.35--0.41)\<0.001**N2**0.67 (0.61--0.74)\<0.0010.67 (0.61--0.73)\<0.001**N3**Reference**ER statusPositive**0.64 (0.59--0.69)\<0.0010.66 (0.61--0.70)\<0.001**Negative**Reference**PR statusPositive**0.51 (0.47--0.55)\<0.0010.64 (0.60--0.68)\<0.001**Negative**Reference**HER2 statusPositive**0.57 (0.53--0.62)\<0.0010.67 (0.63--0.71)\<0.001**Negative**Reference**RadiationNo**1.60 (1.50--1.70)\<0.0011.95 (1.86--2.05)\<0.001**Yes**Reference**ChemotherapyNo**1.46 (1.36--1.57)\<0.0011.89 (1.79--1.99)\<0.001**Yes**Reference**Surgery typeLumpectomy**0.95 (0.89--1.02)0.1651.09 (1.04--1.15)0.001**Mastectomy**Reference[^6][^7][^8][^9]

3.3. Subgroup analysis {#sec3.3}
----------------------

In order to investigate whether MC predicted homogeneous prognosis when stratified by different clinical parameters, we conducted a subgroup analysis to compare the BCSS and OS between MC and IDC in each subgroup. Forest plots of HRs in the univariate Cox analysis summarized the exploratory subgroup analysis of the BCSS and OS are shown in [Fig. 2](#fig2){ref-type="fig"}. Compared with IDC, MC had lower HRs for BCSS in almost all subgroups. In terms of subgroup analysis of OS, MC had higher HRs for OS in grade 1 (HR = 2.07, 95% CI: 1.72--2.50, P \< 0.001), T1 (HR = 1.24, 95% CI: 1.02--1.52, P \< 0.05), N0 (HR = 1.34, 95% CI: 1.16--1.56, P \< 0.001), ER positive (HR = 1.24, 95% CI: 1.07--1.42, P \< 0.01), PR positive (HR = 1.33, 95% CI: 1.15--1.54, P \< 0.001) and lumpectomy (HR = 1.23, 95% CI: 1.03--1.46, P \< 0.05) subgroups. Meanwhile, MC had lower HRs for OS in age ≤60 (HR = 0.46, 95% CI: 0.31--0.70, P \< 0.001), T3 (HR = 0.51, 95% CI: 0.31--0.85, P \< 0.01), underwent radiation (HR = 0.69, 95% CI: 0.53--0.90, P \< 0.01), underwent chemotherapy (HR = 0.44, 95% CI: 0.25--0.76, P \< 0.01) and mastectomy (HR = 0.78, 95% CI: 0.62--0.98, P \< 0.05) subgroups. These data suggested that some clinicopathological markers, such as tumor grade, T and N stage, ER, PR an HER2 status, were important confounders in determining the prognosis of MC patients.Fig. 2Subgroup analysis of mucinous carcinoma. Forest plots of hazard ratios (HRs) of MC versus IDC for BCSS **(A)** and OS **(B)** according to the subgroup analysis. The X-axis shows the HRs and 95% confidence intervals (CIs) of each subgroup. The size of the boxes represents the relative number of patients in each subgroup. Abbreviations: HRs: hazard ratios; BCSS: breast cancer-specific survival; OS: overall survival; MC: mucinous carcinoma; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal receptor 2.Fig. 2

3.4. Transcriptomic and genomic features of breast mucinous adenocarcinoma {#sec3.4}
--------------------------------------------------------------------------

We also utilized the TCGA dataset to explore the transcriptomic and genomic features of MC. In comparison with IDC samples, MC samples were featured by the upregulation of *MUC2*, *CARTPT* and *TFF1* ([Fig. 3](#fig3){ref-type="fig"}A). We also conducted gene set enrichment analysis (GSEA) to investigate the MC-specific pathways. As illustrated in [Fig. 3](#fig3){ref-type="fig"}B, neurotransmitter release-related pathways, including the gamma aminobutyric acid (GABA) synthesis, release and degradation pathway, was upregulated in MC. In addition, we compared the somatic mutational landscape between IDC and MC ([Fig. 3](#fig3){ref-type="fig"}C). MC had significantly lower somatic mutation frequency than IDC in *TP53*, *PIK3CA*, *XIRP2*, *LRBA* and *EYS*. Furthermore, in terms of somatic copy number alterations (SCNA), we observed that 6p25.2, 6q12 and 11q12.3 were significantly amplified in MC ([Fig. 3](#fig3){ref-type="fig"}D). Genes located in these region including *FADS1*, *FADS2*, *FADS3*, *MYRF*, *FEN1* and *FTH1*.Fig. 3Transcriptomic and genomic features of mucinous carcinoma. **(A)** Volcano plot of differentially expressed genes between MC and IDC. **(B)** GSEA analysis of representative MC-specific upregulated pathways. **(C)** Comparison of somatic mutation frequency between MC and IDC. **(D)** Comparison of somatic copy number alterations between MC and IDC. Abbreviations: MC: mucinous carcinoma; IDC: invasive ductal carcinoma; GSEA: gene set enrichment analysis.Fig. 3

4. Discussion {#sec4}
=============

In this study, we retrospectively investigated the clinicopathological characteristics, prognostic significance and genomic features of MC through a comparison with IDC. The results suggested that MC has baseline characteristics that are distinct from those of IDC. A survival analysis indicated that MC was associated with a significantly better BCSS than IDC and similar OS when compared with IDC. However, the difference in BCSS between MC and IDC disappeared after adjusting for confounding factors. Furthermore, multivariate Cox analysis revealed that MC was an independent factor predicting higher HR for OS. In addition, transcriptomic features of MC were correlated with its abundant mucin secretion features. Some MC-specific genomic alterations might contribute to the formation of its pathological features.

As the largest analysis of MC to date, our research took advantage of the high number of SEER datasets to further investigate the clinicopathological characteristics and prognostic significance of MC. We illustrated that MC patients were older, had earlier stage and were more likely to be ER and PR positive and HER2 negative. Therefore, MC patients were less likely to experience radiation, chemotherapy and mastectomy. Most of our results were consistent with those of previous studies \[[@bib12],[@bib20],[@bib21],[@bib25],[@bib26]\]. For example, Elimimian et al. compared the clinicopathological features and prognosis of rare carcinomas of the breast with the data from the National Cancer Database, which enrolled 70,341 breast cancer patients with the rare histological types, and demonstrated that MC had higher proportion of ER and PR positivity, lower HER2 positivity and an overall good prognosis \[[@bib26]\]. However, a retrospective study with 268 MC patients demonstrated that MC patients were younger than IDC patients \[[@bib12]\]. We considered this phenomenon as the patient bias as the enrolled patient number of this study is relatively small and the result of our study was in consistent with most of the other previous studies \[[@bib20],[@bib21],[@bib25]\]. We also analyzed the prognostic value of MC in breast cancer. MC patients showed better BCSS and similar OS when compared with IDC patients. The older median age at diagnosis of MC than IDC could explain the significant difference in BCSS but non-significant difference in OS between the two histological types. However, MC was not an independent prognostic factor for BCSS. After the adjustment for other factors, the prognostic value of MC for BCSS disappeared. This phenomenon suggested the crucial role of confounding factors in determining the BCSS of MC patients, such as the lower grade, higher proportion of ER and PR positivity and lower proportion of HER2 positivity of MC patients, which might contribute to the better BCSS of MC patients. Similarly, previous studies also demonstrated that MC patients had better disease-free survival (DFS) than IDC patients, but the significant prognostic value disappeared after the multivariate Cox analysis \[[@bib12],[@bib21],[@bib27],[@bib28]\]. The similar OS between MC and IDC was also reported in previous studies \[[@bib12],[@bib29]\]. We further demonstrated that after adjusting for confounding factors, MC independently predicted worse prognosis of OS than IDC. This phenomenon suggested that after adjusting for confounding factors, MC patients were more likely to be dead from the reasons except for breast cancer. The reasons for this phenomenon might be related to the genetic background of MC patients, further explorations are needed to explore the relationship between the MC histological type with the risk of diseases other than breast cancer, such as cardiovascular and cerebrovascular diseases.

The other advantage of our study was the comprehensive transcriptomic and genomic analysis of MC. Because of the limited number of samples and the difficulties of high-throughput sequencing in earlier years, previous studies only revealed a few genetic features of MC. MC exhibited a specific molecular identity different from IDC. MC was illustrated to have the lowest levels of gene copy number changes and a lower genetic instability \[[@bib30],[@bib31]\]. Previous study demonstrated that *GATA3*, *KMT2C* and *MAP3K1* were the most frequently mutated genes in pure MCBs \[[@bib23]\]. Two recurrent but not pathognomonic fusion genes, OAZ1-CSNK1G2 and RFC4-LPP, were detected in pure MC \[[@bib23]\]. In addition, MC had fewer concurrent 1q gains and 16q losses \[[@bib23]\]. Previous studies has also demonstrated that MC with the micropapillary features was illustrated to have subtype specific EMA/MUC1 "inside-out" pattern, *GATA3*, *TP53* and *SF3B1* mutation and 17q and 20q gains as well as 17p losses \[[@bib17],[@bib24]\]. In our study, we first analyzed the transcriptomic difference between MC and IDC and illustrated that the upregulated molecules and pathways were related to neurotransmitter secretion, which might contribute to the mucin formation of MC. In addition, we revealed that MC patients had lower somatic mutation frequency of *TP53*, *PIK3CA* and *LRBA*. In addition, MC-specific somatic copy number alterations included the amplification of 6p25.2, 6q12 and 11q12.3 compared with IDC. These specific genomic alterations might be related to the histological features of MC. Some of the results in our study were similar to previous studies. For example, both of our study and the study of Pareja et al. revealed that MC had lower mutation frequency of *TP53* and *PIK3CA*, and *GATA3* was the most frequently mutated gene of MC. However, as the sample size of MC in the two studies were both small, some other top mutated genes of MC were different in the two studies. The mutational landscape of MC need further exploration with larger sample size. In terms of SCNA, Pareja et al. revealed that MC had fewer concurrent 1q gains and 16q losses If we set the cut-off P value for SCNA comparison between MC and IDC into P \< 0.01, we could also conclude that MC had fewer concurrent 1q gains and 16q losses in our study.

Our research also has several limitations. First, it is a retrospective study and may have some potential selection bias. In addition, as the HER2 information in the SEER datasets was not available until 2010, we selected patients from 2010 in SEER database. Therefore, the follow-up period of our study was not very long. Furthermore, as the understanding of MC in our study focused on the bioinformatics analysis of the clinicopathological characteristics and genomic features, further functional validation studies are needed to investigate the biological nature of MC.

In conclusion, MC is a histological subtype that is distinct from IDC with respect to clinicopathological characteristics, prognostic significance and genomic features. The lower grade, higher proportion of ER and PR positivity and lower proportion of HER2 positivity of MC contributed a lot to its better BCSS. In addition, some MC-specific transcriptomic and genomic alterations may contribute to the formation of its histological features.
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